Users Online: 719
Home
About us
Editorial board
Search
Browse articles
Submit article
Ahead of Print
Instructions
Subscribe
Contacts
Login
» Articles published in the past year
To view other articles click corresponding year from the navigation links on the side bar.
All
|
Brief Communication
|
Brief Reports
|
Case Report and Literature Review
|
Case Reports
|
Editorial
|
Erratum
|
Letter to Editor
|
Letters to Editor
|
Notice of Retraction
|
Original Article
|
Original Articles
|
Research Articles
|
Review Articles
|
Review Report
|
Short Communications
|
Systematic Review
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Show all abstracts
Show selected abstracts
Export selected to
Add to my list
Research Article:
In silico
design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin
Soudabeh Akbarzadeh-Sharbaf, Bagher Yakhchali, Zarrin Minuchehr, Mohammad Ali Shokrgozar, Sirous Zeinali
Adv Biomed Res
2012, 1:21 (6 July 2012)
DOI
:10.4103/2277-9175.98122
PMID
:23210080
Background:
There is a novel hypothesis in that antibodies may have specificity for two distinct antigens that have been named "dual specificity." This hypothesis was evaluated for some defined therapeutic monoclonal antibodies (mAbs) such as Trastuzumab, Pertuzumab, Bevacizumab, and Cetuximab. In silico design and construction of expression vectors for trastuzumab monoclonal antibody also in this work were performed.
Materials and Methods:
First, in bioinformatics studies the 3D structures of concerned mAbs were obtained from the Protein Data Bank (PDB). Three-dimensional structural alignments were performed with SIM and MUSTANG softwares. AutoDock4.2 software also was used for the docking analysis. Second, the suitable genes for trastuzumab heavy and light chains were designed, synthesized, and cloned in the prokaryotic vector. These fragments individually were PCR amplified and cloned into pcDNA™ 3.3-TOPO
®
and pOptiVEC™ TOPO
®
shuttle vectors, using standard methods.
Results:
First, many bioinformatics tools and softwares were applied but we did not meet any new dual specificity in the selected antibodies. In the following step, the suitable expression cascade for the heavy and light chains of Trastuzumab therapeutic mAb were designed and constructed. Gene cloning was successfully performed and created constructs were confirmed using gene mapping and sequencing.
Conclusions:
This study was based on a recently developed technology for mAb expression in mammalian cells. The obtained constructs could be successfully used for biosimilar recombinant mAb production in CHO DG44 dihydrofolate reductase (DHFR) gene deficient cell line in the suspension culture medium.
[ABSTRACT]
[HTML Full text]
[PDF]
[Mobile Full text]
[EPub]
[Citations (2) ]
[PubMed]
[Sword Plugin for Repository]
Beta
Feedback
Subscribe
Advanced Search
Month wise articles
Figures next to the month indicate the number of articles in that month
2022
February
[
1
]
2021
November
[
1
]
2018
March
[
1
]
2017
November
[
1
]
2016
November
[
1
]
June
[
1
]
2015
September
[
1
]
July
[
1
]
2013
August
[
1
]
2012
July
[
1
]
Sitemap
|
What's New
Feedback
|
Copyright and Disclaimer
|
Privacy Notice
© Advanced Biomedical Research | Published by Wolters Kluwer -
Medknow
Online since 15 January, 2012